Page 103 - Taiwan Food and Drug Administration 2016 Annual Report

2016 ANNUAL
REPORT

Administration announced the task for ?ling a number of Class 1 medical devices manufactured
in Taiwan would be of?cially started.
b. After completing Cross-Strait exchanges on regulatory laws governing cosmetic products in July
2012, results of legal exchange and comparison were used to discuss collaboration between
testing institutions in Taiwan and Mainland China. In 2015, both parties initiated proficiency
trials and comparisons of testing institutions on micro-organism and heavy metal content testing
in cosmetic products. The aim of this activity was to achieve Mainland Chinese recognition of
test reports produced by Taiwanese institutions, accelerate and improve the efficiency of the
cosmetic product review process, and shorten product release cycle time in Mainland China.
(2) Collaborative Clinical Trials for Medical Products
Medical product agencies of Taiwan and Mainland China jointly formulated the Cross-Strait
Collaboration Program for Clinical Trials of Medical Products and assembled a Medical Product Part II - Key Administrative Results International Cooperation and Cross-Strait Exchanges
Clinical Trial Work Group to accelerate Cross-Strait collaboration for clinical trials of medical
products and reduce the need for repeated testing.
(3) Initiating Joint Inquiry and Review Programs
Open soliciting for Pilot Program for Cross-Strait Collaboration in Medicinal Product Research
and Development and Pilot Program for Cross-Strait Collaboration in Medical Device Research
and Development was carried out in order to build a collaborative framework for the review of
medicinal products and medical devices in Taiwan and Mainland China.
(4) Hosting the Cross-Strait Conference for Collaborative Medical and Medicinal Product Research
and Development
th
The 5 Cross-Strait Conference for Collaborative Medical and Medicinal Product Research
and Development was held in Taipei from November 23 to 24, 2015. Experts and corporate
representatives from Taiwan and Mainland China were invited to the Conference to exchange
opinions and share experiences on various topics such as strategies for Cross-Strait
collaboration for the clinical trials of novel medicinal products.

(5) Hosting the 2015 Summit Meeting of the Task Force for the Management, Research, and
Development of Medical Product Safety

The 2015 Summit Meeting of the Task Force for the Management, Research, and Development
of Medical Product Safety was held at Wuhan, Mainland China, on December 17, 2015. Both
parties acknowledged the work results of 2015 and discussed work plans for 2016.

Figure 2-8-15 4 Cross-Strait Exchange Conference on Medicine and Medical Products Testing Techniques
th
101